Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer
JNCI: Journal of the National Cancer Institute · 01.06.2025 · 117 (6) · 1276-1278
DOI: 10.1093/jnci/djae307 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 03.12.2024. Verfasst von Jacob B Reibel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States. Hauptthemen laut MEDLINE: Neoplasms, Carboplatin, Cisplatin, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS, NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The recent cisplatin and carboplatin (“platinum”) chemotherapy shortage, first announced on February 10, 2023, has impacted cancer patients nationwide. Here, we quantify the extent to which the shortage affected platinum chemotherapy prescribing and short-term mortality. This cohort study included 11 797 adults with advanced solid cancers who initiated first-line therapy during the 1-year period before (February 1, 2022–February 9, 2023) or during (February 10, 2023–January 31, 2024) the platinum shortage. During the shortage, there was a 2.7% absolute reduction in platinum use (95% CI = −4.4% to −0.9%) compared to the previous year. At the peak of the shortage, there was a 15.1% absolute reduction in platinum prescribing (June 2023: 57.8% [95% CI = 53.6% to 62.0%]) compared to 1 year prior (June 2022: 72.9% [95% CI = 70.7% to 75.2%]). There was no difference in mortality before vs during the shortage (adjusted hazard ratio 1.00; 95% CI = 0.94 to 1.07) with median follow-up time of 7.6 months. Further research is required to study shortage impacts on long-term mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.
- Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA 19104, United States.
- Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.
- Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA 19104, United States.
- Department of Biostatistics, Brown University School of Public Health, Providence, RI 02903, United States.
ORCID-Profile: Jacob B Reibel, Lova L Sun, Ravi B Parikh, Nadim Mahmud, Lainie P Martin, Rebecca A Hubbard, Ronac Mamtani
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Reibel, J. B., Sun, L. L., Parikh, R. B., Mahmud, N., Martin, L. P., Hubbard, R. A., & Mamtani, R. (2025). Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer. JNCI: Journal of the National Cancer Institute, 117(6), 1276-1278. https://doi.org/10.1093/jnci/djae307
Vancouver
Reibel JB, Sun LL, Parikh RB, Mahmud N, Martin LP, Hubbard RA, et al. Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer. JNCI: Journal of the National Cancer Institute. 2025;117(6):1276-1278. doi:10.1093/jnci/djae307
BibTeX
@article{Reibel2025,
author = {Reibel, Jacob B and Sun, Lova L and Parikh, Ravi B and Mahmud, Nadim and Martin, Lainie P and Hubbard, Rebecca A and Mamtani, Ronac},
title = {Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
volume = {117},
number = {6},
pages = {1276--1278},
doi = {10.1093/jnci/djae307}
}
EUVIMED